# A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

> **NCT01853254** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 272 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT01853254
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2013-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01853254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01853254, "A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01853254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*